account/PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that it has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application for...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Perrigo's Partner Synthon Receives FDA Tentative Approval For Levocetirizine Solution - Generic Equivalent To Xyzal�� Oral Solution
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account